Kopin Corporation (Nasdaq: KOPN) — FY2023 Form 10-K
Reporting period: Fiscal year ended December 30, 2023 (52 weeks), compared with the year ended December 31, 2022 (53 weeks). The filing is an annual report, not a separate fourth-quarter report. Amounts below are U.S. dollars.
Business context
Kopin develops microdisplays, optics, subassemblies and headsets, primarily for defense, industrial, medical and 3D optical inspection applications. It is shifting toward application-specific optical solutions rather than displays alone. Defense customers and funded development contracts are central to revenue; consumer AR/VR remains a potential market rather than an established growth driver.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Total revenue | $40.4 million | $47.4 million |
| Net product revenue | $25.9 million | $32.4 million |
| R&D revenue | $13.5 million | $14.4 million |
| Operating loss | $17.2 million | $21.8 million |
| Net loss attributable to Kopin | $19.7 million | $19.3 million |
| Basic and diluted loss per share | $0.18 | $0.21 |
| Cash used in operating activities | $15.3 million | $17.7 million |
| Cash, restricted cash and marketable debt securities | $17.9 million | $12.6 million |
| Working capital | $24.0 million | $16.4 million |
Revenue declined about 15%. Product cost was 96.2% of net product revenue, implying a thin product gross margin of about 3.8%, versus approximately zero in FY2022. The reported loss from operations equaled about 42.5% of revenue; net loss equaled about 48.9%. The filing reports no conventional borrowings; lease liabilities were $2.5 million, including $0.7 million current. Year-end current assets were $39.8 million and current liabilities $15.9 million.
Cash and marketable securities increased mainly because Kopin raised $22.9 million gross in a January 2023 equity and pre-funded warrant offering. In February 2024, it sold 3.1 million additional shares for $7.5 million gross, or $7.3 million net. The February financing occurred after year-end and increased the share count. The company reported 118.4 million common shares outstanding on March 7, 2024.
Changes versus the prior period
- Defense revenue by application declined to $22.6 million from $24.8 million, largely due to fewer thermal weapon sight shipments; pilot helmet and training/simulation sales partly offset the decline.
- Industrial/enterprise revenue fell to $2.7 million from $6.1 million, mainly reflecting lower 3D metrology and industrial headset sales. Consumer revenue declined to $0.6 million from $1.5 million.
- R&D revenue decreased to $13.5 million from $14.4 million, while funded R&D expense fell to $7.2 million from $10.3 million and internal R&D expense to $3.6 million from $8.4 million.
- SG&A increased to $21.8 million from $18.0 million, principally due to about $5.0 million more in legal and professional fees and $1.0 million more in stock compensation, partly offset by lower compensation and benefits.
- Operating loss narrowed, but net loss edged higher. Non-operating results swung from $2.6 million of income in FY2022 to $2.4 million of expense in FY2023, including $3.3 million of investment remeasurement/impairment losses. FY2022 included a $4.7 million investment revaluation gain.
Outlook, risks and unusual items
- Management expects negative operating cash flow in FY2024 and continues to invest in research and development. It estimated year-end liquidity would fund operations at least through Q1 2025; after the February 2024 share sale, the filing says available resources should cover at least 12 months from the financial statements’ issuance. Additional capital may be needed if results fall short.
- Management cited operational improvements and curtailment of certain development programs as measures intended to preserve cash. No specific revenue, margin or profitability guidance was provided.
- FWS-I product quality issues led to shipment suspensions at various times in 2023. Production-process changes continued, and Kopin warns that program qualification, U.S. defense funding, contract awards and customer orders are uncertain.
- Supply-chain risks remain, including long lead times for some semiconductor components and dependence on a limited number of foundries, particularly in Taiwan and China. Kopin is transitioning certain OLED deposition work from a Chinese to a European foundry.
- Fixed-price contracts expose Kopin to cost overruns, and customer purchase orders are generally short-term and cancellable. Revenue on certain development contracts depends on cost-to-cost estimates; the auditor identified R&D revenue recognition as a critical audit matter due to management’s cost estimates.
- Kopin recorded a $3.1 million impairment on its RealWear investment and other investment losses; total equity investments were $4.7 million at year-end. The Lightning Silicon Technology spinout gave Kopin a 20% interest and potential royalties; its carrying value was reported as zero at year-end.
- The BlueRadios intellectual-property dispute remained pending, with trial set for March 20, 2024. Kopin said a loss was not considered probable and recorded no accrual. The filing does not provide a clear estimate of potential exposure.
- The company reported an accumulated deficit of $358.2 million and operating cash outflows in each of FY2021–FY2023. Equity issuance has helped fund operations and diluted existing holders. FY2023 controls were assessed by management as effective; the auditor did not audit internal control over financial reporting.
Key facts for investors to verify
- Whether FWS-I quality remediation is complete and shipments, yields and warranty costs are stabilizing.
- Actual cash burn, liquidity runway and the terms and dilution impact of future ATM or other financings.
- Revenue conversion from defense development programs into production orders, including customer concentration: DRS represented 33% and Collins Aerospace 27% of FY2023 revenue.
- Availability and cost of critical components, and progress and qualification results for the European OLED foundry transition.
- Updates on the BlueRadios litigation and any resulting financial or intellectual-property exposure.
- Commercialization progress and economics for OLED and MicroLED products, and whether the reported low product margin improves.